Study identified predictive factors for neuroendocrine tumor progression HemOncToday Researchers also found that a combination of the drug everolimus (Afinitor, Novartis) with octreotide acetate arrested neuroendocrine tumor development longer vs. octreotide treatment alone. “We have identified important prognostic factors that can ... |
